

FINTEC GLOBAL BERHAD

(FORMERLY KNOWN AS ASIA BIOENERGY TECHNOLOGIES BERHAD)
(Company No. 774628-U)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE 2ND QUARTER AND YEAR-TO-DATE ENDED 30 SEPTEMBER 2018

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER AND YEAR-TO-DATE ENDED 30 SEPTEMBER 2018

(The figures have not been audited)

	Quarter Ended		Year-To-Date Ended		ded	
	30.09.2018	30.09.2017	Changes	30.09.2018	30.09.2017	Changes
	RM'000	RM'000	%	RM'000	RM'000	%
Revenue	8,890	7,959	11.7	9,327	9,868	(5.5)
Cost of sales	(8,062)	(4,563)	(76.7)	(8,148)	(6,823)	(19.4)
Gross profit	828	3,396	(75.6)	1,179	3,045	(61.3)
Other operating income	1,771	177	900.6	2,143	484	342.8
Operating expenses	(1,306)	(1,471)	11.2	(2,554)	(5,743)	55.5
Fair value gain/(loss) on investment securities	11,027	19,053	(42.1)	(19,951)	62,543	(131.9)
Finance costs	(63)	(72)	12.5	(125)	(173)	27.7
Profit/(Loss) before taxation	12,257	21,083	(41.9)	(19,308)	60,156	(132.1)
Tax expense	-	(332)	-	-	(332)	-
Profit/(Loss) for the period	12,257	20,751	(40.9)	(19,308)	59,824	(132.3)
Other comprehensive loss: Items that may be subsequently reclassified to profit or loss:						
Foreign currency translation differences for foreign						
operations	8	-	-	7	-	-
Total comprehensive income/(loss) for the period	12,265	20,751	(40.9)	(19,301)	59,824	(132.3)
Profit/(Loss) attributable to:						
Owners of the Company	12,260	20,755	(40.9)	(19,301)	59,843	(132.3)
Non-controlling interest	(3)	(4)	25.0	(7)	(19)	63.2
	12,257	20,751	(40.9)	(19,308)	59,824	(132.3)
Total comprehensive income/(loss) attributable to:						
Owners of the Company	12,268	20,755	(40.9)	(19,294)	59,843	(132.2)
Non-controlling interest	(3)	(4)	25.0	(7)	(19)	63.2
	12,265	20,751	(40.9)	(19,301)	59,824	(132.3)
			Quarte	r Ended	Year-To-D	ate Ended
			30.09.2018	30.09.2017	30.09.2018	30.09.2017
			Sen per	Sen per	Sen per	Sen per
			share	share	share	share
(Loss)/Earnings Per Share attributable to equity	<i>I</i>					(Audited)
owners of the Company (sen)	•					
- Basic			2.30	4.67	(3.30)	14.38
- Diluted			0.85	3.61	N/A	10.93

Notes:

The condensed consolidated statements of comprehensive income are prepared based on the consolidated results of the Group for the quarter ended 30 September 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 SEPTEMBER 2018

(The figures have not been audited)		
	Unaudited	Audited
	As at 30.09.2018	As at 31.03.2018
	RM'000	RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	2,973	3,154
Investment securities	107,235	124,469
	110,208	127,623
Current assets		
Receivables, deposits and prepayments	24,375	11,030
Investment securities	24,373 272	235
Investment in unquoted shares	2,000	-
Deposit with Financial Institution	41,062	60,568
Inventories	294	321
Cash and cash equivalents	4,447	2,537
out and out oquivalent	72,450	74,691
TOTAL ASSETS	182,658	202,314
EQUITY AND LIABILITIES		
Share capital	94,150	81,873
ICPS	44,529	53,228
Reserves	11,466	11,459
Retained profits	19,509	38,810
Total equity attributable to owners of the Company	169,654	185,370
Non-controlling interest	(1,643)	(1,636)
Total equity	168,011	183,734
Current lightlities		
Current liabilities Payables and accruals	14,641	18,574
Current tax liabilities	6	10,574
Total current liabilities	14,647	18,580
Total liabilities	14,647	18,580
TOTAL EQUITY AND LIABILITIES	182,658	202,314
Net assets per share attributable to equity holders of the		

Notes:

The condensed consolidated statement of financial position is prepared based on the consolidated results of the Group for the quarter ended 30 September 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

Net assets per share is arrived at based on the total Group's net assets over the 602,543,672 ordinary shares in issue as at 30 September 2018.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR-TO-DATE ENDED 30 SEPTEMBER 2018

(The figures have not been audited) ----- Attributable to Owners of the Company ----<-----> Non-distributable -----> Distributable (Accumulated Exchange Nonlosses)/ Share Share Warrant Translation controlling Total ICPS Premium Capital Reserve Reserve Retained profits Total Interest Equity RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 RM'000 Audited Balance as at 1 April 2017 56,005 1,298 334 (4,629)53,008 (1,562)51,446 Total comprehensive profit for the period 43,439 43.439 (74)43,365 Transaction with owners of the Company: Issuance of ICPS with free warrants 61,367 10.575 71,942 71,942 Issuance of ordinary shares pursuant to conversion of ICPS 12,073 (8,139)3,934 3,934 Issuance of ordinary shares pursuant to SIS 13,782 13,782 13,782 8 Issuance of ordinary shares pursuant to exrcise of Warrant B 13 (5) 8 Share issuance expenses (743)(743)(743)Total transctions with owners of the Company 25,868 53,228 (743)10,570 88,923 88,923 81,873 53,228 555 38,810 185,370 Balance as at 31 March 2018 10,904 (1,636)183,734 Unaudited Balance as at 1 April 2018 81,873 53,228 555 10,904 38,810 185,370 (1,636)183,734 (19,301)(7) Loss for the period (19,301)(19,308)7 Other comprehensive loss 7 7 (19,301)(19,294)(7) (19,301)Total comprehensive loss for the period Transaction with owners of the Company: Issuance of ordinary shares pursuant to conversion of ICPS 12,277 (8,699)3,578 3,578 Balance as at 30 September 2018 94.150 44.529 555 10.904 7 19.509 169.654 (1.643)168.011

Notes:

The condensed consolidated statement of changes in equity is prepared based on the consolidated results of the Group for the quarter ended 30 September 2018 and is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

(Formerly known as Asia Bioenergy Technologies Berhad)
(Company No. 774628-U)
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEAR-TO-DATE ENDED 30 SEPTEMBER 2018

(The figures have not been audited)

	Year-To-Date Ended		
	30.09.2018	30.09.2017	
CASH FLOWS FROM OPERATING ACTIVITIES	RM'000	RM'000	
(Loss)/Profit before tax	(19,308)	60,156	
Adjustments for :			
Depreciation of property, plant and equipment	188	502	
Interest income	(824)	(5)	
Gain on disposal of investment	-	(40)	
Share-based payment reserve	-	1,990	
(Gain)/loss on disposal of investment securities	(396)	6	
Fair value loss/(gain) on investment securities	19,951	(62,543)	
Gain on unrealised foreign exchange Interest expense	(642) 125	(238) 173	
Operating (loss)/gain before working capital changes	(906)	173	
Changes in working capital:			
Proceeds from disposal of investment securities	8,503	3,934	
Purchase of investment securities	(10,859)	(27,397)	
Decrease/(Increase) in inventories	27	(25)	
Increase in trade and other receivables	(13,269)	(6,674)	
(Decrease)/Increase in trade and other payables Cash used in operations	(3,765) (20,269)	19,731 (10,430)	
Income tax paid	(76)	(10,400)	
Interest received		5	
Net cash used in operating activities	(20,345)	(10,425)	
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment	(6)	(14)	
Proceeds from disposal of investment	-	40	
Interest received	824	-	
Purchase of unquoted shares	(2,000)	- (E12)	
Share premium Net cash generated from investing activities	(1,182)	(512) (486)	
CASH FLOWS FROM FINANCING ACTIVITIES	(1,102)	(100)	
Proceeds from issuance of shares pursuant to SIS			
of ICPS	3,577	11,792	
Borrowing	-	(721)	
Interest paid	(125)	(173)	
Net cash generated from financing activities	3,452	10,898	
Net decrease in cash and cash equivalents	(18,075)	(13)	
Effect of exchange rate changes	479	-	
Cash and cash equivalents at beginning of the year	63,105	194	
Cash and cash equivalents at end of the period	45,509	181	
Cash and cash equivalents consist of:			
Deposits with lincensed financial instituition	41,062	-	
Cash and bank balances	4,447	181	
	45,509	181	
Al. a			

Notes:

The condensed consolidated statements of cash flow for the quarter ended 30 September 2018 is to be read in conjunction with the audited consolidated financial statements for the financial year ended 31 March 2018 and the accompanying explanatory notes attached to these interim financial statements.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

A1 Basis of preparation

The interim financial statements are unaudited and have been prepared in accordance with Malaysia Financial Reporting Standards ("MFRSs") 134: Interim Financial Reporting, International Financial Reporting Standards ("IFRSs") 134: Interim Financial Reporting and paragraph 9.22 of the ACE Market Listing Requirements ("AMLR") of Bursa Malaysia Securities Berhad ("Bursa Securities").

The interim financial statements should be read in conjunction with the Group's audited consolidated financial statements for the financial year ended 31 March 2018. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 March 2018.

The accounting policies and methods of computation adopted by the Group in this interim financial statements is consistent with those adopted in the audited financial statements for the financial year ended 31 March 2018 except for the adoption of the following MFRSs and amendments to MFRSs which came into effect for annual periods beginning on or after 1 January 2018 and are applicable for the Group's interim financial statements for the quarter and year-to-date ended 30 September 2018, as disclosed below:

MFRSs, Amendments to MFRSs and IC Interpretation

MFRS 9 Financial Instruments

MFRS 15 Revenue from Contracts with Customers

MFRS 15 Clarifications to MFRS 15

Amendments to MFRS 2 Classification and Measurement of Share-based Payment Transactions

Amendments to MFRS 140 Transfer of Investment Property

IC Interpretation 22 Foreign Currency Transactions and Advance Consideration

Annual Improvements to MFRS Standards 2014 - 2016 Cycles:

- Amentmends to MFRS 1 Deletion of Short-term Exemptions for First-time Adopters
- Amentmends to MFRS 128 Measuring an Associate or Joint Venture at Fair Value

The adoption of the above standards and interpretation are not expected to have a material impact on the financial statements in the period of application except as discussed below:

MFRS 9 Financial Instruments

MFRS 9 introduces new requirements for classification and measurement of financial assets, impairment of assets and hedge accounting. Financial assets are classified according to their contractual cash flow characteristics and the business model under which they are held. The impairment requirements in MFRS 9 are based on expected credit loss model and replace the MFRS 139 Financial Instruments: Recognition and Measurement incurred loss model.

MFRS 9 if effective for annual periods beginning on or after 1 January 2018, with early application permitted. Retrospective application is required, but comparative information is not compulsory. The Group applied the new standard without restating comparative information and recognises any difference between the previous carrying amount and the carrying amount at the beginning of the annual reporting period at the date of initial application in the opening retained earnings. Based on the preliminary assessment of the adoption of MFRS 9, the Group concluded that the new standard did not have a significant impact to the interim financial statements.

The Group applied the simplified approach and assessed the lifetime expected losses on trade receivable, which did not have a material impact on the impairment allowance.

MFRS 15 Revenue from Contracts with Customers

MFRS 15 establishes a single comprehensive model for revenue recognition. Under MFRS 15, revenue is recognised at an amount that reflects the consideration which an entity expects to be entitled in exchange for transferring goods or services to a customer.

The new standard will supersede all current revenue recognition requirements under MFRS. Either a full retrospective application or a modified retrospective application is required for annual periods beginning on or after 1 January 2018.

MFRS 15 provides a single model for accounting for revenue arising from contracts with customers, focusing on the identification and satisfaction of performance obligations, i.e. when 'control' of the distinct promised goods or services underlying the particular performance obligation is transferred to the customers.

The adoption of this new MFRS 15 did not have a significant impact on the results and financial position of the Group.

(Formerly known as Asia Bioenergy Technologies Berhad)
(Company No. 774628-U)
(Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

A2 Auditors' report on preceding annual financial statements

There were no audit qualifications in relation to the audited consolidated financial statements of the Group for the financial year ended 31 March 2018.

A3 Seasonal or cyclical factors

There were no significant seasonal or cyclical factors that will materially affect the business of the Group in current period. However, the Group's results are largely influenced by, amongst others, the market prices of quoted investments as well as the timing of disposal of investments by the Group.

A4 Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter and financial year-to-date ended 30 September 2018.

A5 Material changes in estimates

There were no changes in estimates that have a material effect in the current financial quarter and financial year-to-date results.

A6 Debt and equity securities

Save as disclosed in the following, there were no issuance, cancellations, repurchases, resale and repayment of debt and equity securities, share buy backs, share cancellation, shares held as treasury share and resale of treasury shares during the current financial quarter and financial year-to-date ended 30 September 2018.

a) During the financial year to date, the Company issued new ordinary shares pursuant to the conversion of ICPS are as below:

	Quarter E	Quarter Ended		Year-To-Date Ended	
	30.09.2	018	30.09.2018		
	No. of shares	RM'000 No	o. of shares	RM'000	
	'000		'000		
Conversion of ICPS	10,801	1,728	76,729	12,277	

A7 Dividend paid

There were no dividends paid by the Group during the financial quarter ended 30 September 2018.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

A8 Segmental information

Segment information based on the Group's activities is set out below. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

Cumulative Quarter Ended 30 September 2018

	Incubation RM'000	Portfolio Investment RM'000	Green Technology products RM'000	O & G services RM'000	Elimination RM'000	Group RM'000
Revenue						
External sales	824	8,503	-	-	-	9,327
Intersegment		-	-	-	-	
	824	8,503	-	-	-	9,327
Results from operating activities	-	(18,999)	(128)	1,404		(17,723)
Finance costs		(125)				(125)
Share of profit of associates						-
Net unallocated expenses						(1,460)
Profit before taxation					-	(19,308)
Tax expense						-
Profit for the period					- -	(19,308)
Segment assets	52,991	119,389	1,334	3,880		177,594
Unallocated assets						5,064
Total assets					- -	182,658
Segment liabilities Unallocated liabilities	8,575	19	246	5,800		14,640 7
Total liabilities					-	14,647

A9 Valuation of property, plant and equipment

There was no valuation of the property, plant and equipment during the current financial quarter and year-to-date ended 30 September 2018.

A10 Material events subsequent to the end of the quarter

Save as disclosed in Note B11, there were no material events occurring subsequent to the end of the current quarter.

A11 Changes in the composition of the Group

Save as disclosed in Note B11, there were no changes in the composition of the Group during the current quarter and year-to-date ended 30 September 2018.

A12 Contingent liabilities

The Company provides corporate guarantees amounting to RM3.385 million (as at 31 March 2017: RM NIL) in lieu of security deposits required by suppliers for leasing of scaffolding equipment to a wholly owned subsidiary. Consequently, the Company is contingently liable for the amounts of corporate guarantees fully utilised by the wholly owned subsidiary.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part A - Explanatory Notes Pursuant to Malaysia Financial Reporting Standard ("MFRS") 134 and ACE Market Listing Requirements of Bursa Malaysia Securities Berhad

A13 Capital commitments

As at 30 September 2018, the Group has no material capital commitments.

A14 Related party transactions

During the financial quarter ended 30 September 2018, the Directors are of the opinion that the Group has no related party transactions which would have a significant impact on the financial position and business of the Group.

A15 Additional Disclosure Requirements to the Statements of Comprehensive Income

	Quarter Ended		Year-To-Date Ended	
	30.09.2018	0.09.2018 30.09.2017	30.09.2018	30.09.2017
	RM'000	RM'000	RM'000	RM'000
Interest income	387	5	824	5
Other income	-	175	-	175
Interest expense	(63)	(72)	(125)	(173)
Depreciation and amortisation	(94)	(243)	(188)	(502)
Gain of disposal of quoted or unquoted investments				
or properties (non revenue)	-	-	-	40
Fair value (loss)/gain on marketable securities	11,027	19,053	(19,951)	62,543
Unrealised Foreign exchange gain/(loss)	270	(28)	642	238

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Bo

B1 Performance review

a) Current Quarter vs. Previous Year Corresponding Quarter

	Quarter Ended				
	30.09.2018	30.09.2017	Change	es	
Key Profit or Loss items:	RM'000	RM'000	RM'000	%	
Revenue	8,890	7,959	931	11.7	
Profit Before Tax	12,257	21,083	(8,826)	(41.9)	
Net profit attributable to equity holders	12,260	20,755	(8,495)	(40.9)	

The Group's revenue for the current quarter ending 30 September 2018 was RM8.89 million, an increase of RM0.931 million or 11.7% as compared to RM7.959 million in the previous year's corresponding quarter. The revenue for the quarter was generated from the sale of short term marketable securities and interest income received from fixed deposits placed with financial institution.

The Group made a profit before tax of RM12.257 million for the current quarter as opposed to a profit before tax of RM21.083 million in the corresponding quarter ending 30 September 2017 and the net profit attributable to equity holders was RM12.26 million, representing a decrease in profit of RM8.496 million or -40.9% as compared to a net profit attributable to equity holders of RM20.755 million in previous year's corresponding quarter.

The decrease of profits mainly due to the reduction in fair value on quoted securities of RM8.026 million arising from the general reduction in market prices of such quoted securities. The poor performance of these quoted securities is reflective of the poor market sentiment and performance of our local bourse and the regional markets.

Performance of the respective operating business segments for the 2nd quarter ending 30 September 2018 as compared to the previous corresponding quarter is analysed as follows:-

Profit/(Loss) Before Tax by Segments	Quarter Ended				
	30.09.2018	30.09.2017	Changes		
	RM'000	RM'000	RM'000	%	
Portfolio investment	11,687	19,224	(7,537)	(39.2)	
Green technology products	(75)	(141)	66	46.8	
O & G services	(1,336)	3,352	(4,688)	(139.9)	

Portfolio investment

Loss before tax reduced by RM7.537 million (-39.2%) to RM11,687 million mainly due to the reduction in market prices of the Group's strategic investments in Malaysia which were affected by the poor local market performance and lack lustre regional bourses.

Green technology products

Loss before tax reduced by RM0.066 million (46.8%) to RM0.075 million, mainly due to a decrease in depreciation for plant and machineries.

O & G services

Profit before tax reduced by RM4.688 million (1.4x) to RM1.336 million. The decrease of profit was mainly due to cessation of the Oil & Gas services business.

b) Current Year-to-date vs. Previous Year-to-date

	Year-To-Date Ended				
	30.09.2018	30.09.2017	Chang	es	
Key Profit or Loss items:	RM'000	RM'000	RM'000	%	
Revenue	9,327	9,868	(541)	(5.5)	
(Loss)/Profit Before Tax	(19,308)	60,156	(79,464)	(132.1)	
Net (loss)/profit attributable to equity holders	(19,301)	59,843	(79,144)	(132.3)	

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Bo

B1 Performance review (Cont'd)

b) Current Year-to-date vs. Previous Year-to-date (Cont'd)

	Year-To-Date Ended				
	30.09.2018	30.09.2017	Change	es	
Key Balance Sheet Items:	RM'000	RM'000	RM'000	%	
Investment securities :-					
Non-current	107,235	124,366	(17,131)	(13.8)	
Current	272	7,961	(7,689)	(96.6)	
	107,507	132,327	(24,820)	(18.8)	
Trade and other payables	14,641	21,117	(6,476)	30.7	

The Group's revenue for the year-to-date ending 30 September 2018 was RM9.327 million, a decrease of RM0.541 million or -5.5% as compared to RM9.868 million in the previous year's corresponding period. The decrease in revenue for the quarter was mainly due to the cessation of the Oil & Gas services business.

The Group made a loss before tax of RM19.308 million for the year-to-date as opposed to profit before tax of RM60.156 million in the corresponding period ending 30 September 2017 and the net loss attributable to equity holders was RM19.301 million, an increase of loss of RM79.144 million or -1.32x as compared to the net profit attributable to equity holders of RM59.843 million in previous year's corresponding period.

The increase of losses is mainly due to the fair value loss on quoted securities of RM82.494 million arising from the general reduction in market prices of such quoted securities. The poor performance of these quoted securities was in line with the poor market sentiments and lack lustre performance of our local bourse and the regional markets.

The Group's investment in marketable securities reduced by RM24.82 million or -18.8% to RM107.507 million as at 30 September 2018 as compared to RM132.327 million as at 30 September 2017, which was mainly due to fair value loss on the quoted securities arising from the reduction in market prices of such quoted securities and the sold of short term marketable securities during the reporting period.

Total Trade and other payables decreased by 30.7% or RM6.476 million over the same period to RM14.641 million as at 30 September 2018, which was mainly due to the decrease in payables for medium to long term portfolio investments of approximately RM 6.484 million.

Performance of the respective operating business segments for the year-to-date ending 30 September 2018 as compared to the previous corresponding period is analysed as follows:-

	Year-To-Date Ended				
	30.09.2018	30.09.2017	Chang	es	
(Loss)/Profit Before Tax by Segments	RM'000	RM'000	RM'000	%	
Portfolio investment	(19,124)	62,562	(81,686)	(130.6)	
Green technology products	(128)	(307)	179	58.3	
O & G services	1,404	1,340	64	4.8	

Portfolio investment

Loss before tax increased by RM81.686 million (-1.31x) to RM19.124 million which was mainly due to the reduction in market prices of the Group's strategic investments in Malaysia which was affected by the poor local market performance and lack lustre regional bourses.

Green technology products

Loss before tax reduced by RM0.179 million (58.3%) to RM0.128 million mainly due to a decrease in depreciation for plant and machineries.

O & G services

Profit before tax increased by RM0.064 million (4.8%) to RM1.404 million mainly due to a decrease in administration and general overhead during the current quarter.

(Formerly known as Asia Bioenergy Technologies Berhad)
(Company No. 774628-U)
(Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Bo

B2 Variation of results against immediate preceding quarter

	Current	Preceding	
	quarter	quarter	
	30.09 2018	30.06.2018	Changes
	RM'000	RM'000	%
Revenue	8,890	437	1,934.3
Profit/(Loss) before taxation	12,257	(31,565)	138.8

The Group registered revenues of RM8.89 million for the current quarter ending 30 September 2018, an increase of RM8.453 million or 19.34x as compared to RM0.437 million for the immediate preceding quarter ending 30 June 2018. The increase in revenue was mainly due to quoted securities traded during the current period.

Profit before taxation incurred by the Group for the 2nd quarter ending 30 September 2018 was RM12.257 million, an improvement of RM43,822 million or 1.39x as compared to a loss before tax of RM31.565 million in the preceding quarter. The improvement in profit before tax was mainly due to the sale of short term marketable securities and fair value loss accounted for in the preceding quarter.

B3 Prospects

As the Group's performance is principally driven by its investments in marketable securities which is represented by it's listed incubatees, the Group's results will always be subjected to unpredictable market forces. Management is however cautiously optimistic that the performance of its incubatees in the medium term will improve once the market stabilizes. In the interim, management is actively examining several potential investments and incubation projects and will be making the relevant disclosures in due course.

B4 Profit forecast, profit guarantee and internal targets

The Group did not provide any profit forecast, profit guarantee or made public any internal targets for the period under

B5 Income tax expense

During the financial quarter ended 30 September 2018, no provision for taxation needed to be provided as the Group had adequate unabsorbed tax losses brought forward from previous years to offset the profit incurred, if any, in the current financial quarter.

B6 Trade Receivables

	As at	
	30.09.2018	30.09.2017
	RM'000	RM'000
Trade receivables	822	7,814

The ageing analysis of the Group's trade receivables to non-related parties as at 30 September 2018 is as follows:

	AS	As at		
	30.09.2018	30.09.2017		
	RM'000	RM'000		
Neither past due nor impaired	796	7,653		
Past due not impaired:				
91 - 180 days	-	42		
> 181 days	26	119		
Impaired	-	-		
	822	7,814		

(Formerly known as Asia Bioenergy Technologies Berhad)
(Company No. 774628-U)
(Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Bo

B7 Group's borrowings and debt securities

The Group has no borrowing or debt securities as at end of the reporting date.

B8 Material litigation

As at this reporting date, neither the Company nor its subsidiary companies are engaged in any litigation or arbitration, either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiary companies and the Board is not aware of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings, which might materially and adversely affect the position or business of the Company or its subsidiary companies.

B9 Dividends

There were no dividends declared for the financial quarter ended 30 September 2018.

B10 Earnings per share ("EPS")

a) Basic EPS

•	Quarter Ended		Year-To-Date Ended	
	30.09.2018	30.09.2017	30.09.2018	30.09.2017
Profit/(Loss) attributable to the owners of the				
Company (RM'000)	12,260	20,755	(19,301)	59,843
Weighted average number of ordinary shares in issue ('000)	533,201	444,308	584,982	416,088
Basic EPS (sen)	2.30	4.67	(3.30)	14.38
1) 5" (1550				

b) Diluted EPS

	Quarter Ended		Year-To-Date Ended	
	30.09.2018	30.09.2017	30.09.2018	30.09.2017
Profit/(Loss) attributable to the owners of the				
Company (RM'000)	12,260	20,755	(19,301)	59,843
Weighted average number of ordinary shares in issue ('000)	533,201	444,308	584,982	416,088
Effective of dilution from conversion of ICPS ('000)	688,811	-	688,811	-
Effective of dilution from detachable warrants A ('000)	131,296	131,296	131,296	131,296
Effective of dilution from detachable warrants B ('000)	89,883		89,883	
Adjusted weighted average number of ordinary shares				
in issue and issuable ('000)	1,443,191	575,604	1,494,972	547,384
Diluted EPS (sen)	0.85	3.61	N/A	10.93

The diluted EPS is computed based on the profit attributable to the owners of the Company divided by the weighted average number of ordinary shares in issue during the financial period and assume the full conversion of the ICPS and warrants into ordinary shares.

B11 Status of corporate proposals

a) On 18 October 2018, the Company undertook an internal restructuring within the Group via a transfer of one (1) ordinary share representing 100% of share capital of Tenisha Asiabio Petroleum Sdn. Bhd. ("TAP") from Asiabio Petroleum Sdn. Bhd. to the Company for a cash consideration of RM1.00. Consequent to the internal restructuring, TAP shall become a 100% direct-owned subsidiary of FINTEC.

(Formerly known as Asia Bioenergy Technologies Berhad) (Company No. 774628-U) (Incorporated in Malaysia)

Part B - Disclosure requirements as set out in Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Bo

B12 Status of Utilisation of Proceeds

Status of utilisation of proceeds as at 30 September 2018.

Rights issue of ICPS with warrants	Proposed Utilisation RM'000	Actual Utilisation RM'000	Unutilised proceeds RM'000	Reallocatio n RM'000	Timeframe for the utilisation of proceeds
i) Investment in quoted securities - Focus ICPS	10,489	-	10,489	-	Within 12 months
ii) Investment in quoted securities - Vsolar Rights Shares	8,200	-	8,200	-	Within 12 months
iii) Working capital	5,000	(3,832)	1,168	204	Within 24 months
iv) Investment in unquoted incubatees and/or start-up companies to be identified	47,410	(4,152)	43,258	-	Within 36 months
v) Estimated expenses	844	(640)	204	(204)	immediate
_	71,943	(8,624)	63,319		

B13 Non-cash items to the Condensed Consolidated Statement of Comprehensive Income

	Quarter Ended		Year-To-Date Ended	
	30.09.2018	30.09.2017	30.09.2018	30.09.2017
	RM'000	RM'000	RM'000	RM'000
Total Comprehensive (Loss)/Profit	12,257	20,751	(19,308)	(59,824)
Non-Cash items:				
Depreciation of property, plant and equipment	(94)	(243)	(188)	(502)
Gain/(Loss) on unrealised foreign exchange	270	(28)	642	238
Gain/(Loss) on change in fairvalue	11,027	19,053	(19,951)	62,543
Share-based payment reserve	-	(727)	-	(1,990)
	11,203	18,055	(19,497)	60,289
Total Comprehensive loss before non-cash items	1,054	2,696	189	(465)

B14 Authorisation for issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with the resolution of the Board of Directors.

On Behalf of the Board

Leung Kok Keong Lim Lee Kuan Ng Sally Company Secretaries